Published in Eur J Biochem on March 01, 1994
The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A (2000) 5.46
Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A (2003) 5.05
Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol (2006) 4.88
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84
A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol (2003) 3.44
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2006) 2.61
Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses. Proc Natl Acad Sci U S A (1995) 1.40
Cloning of a gene (RIG-G) associated with retinoic acid-induced differentiation of acute promyelocytic leukemia cells and representing a new member of a family of interferon-stimulated genes. Proc Natl Acad Sci U S A (1997) 1.14
Forced IFIT-2 expression represses LPS induced TNF-alpha expression at posttranscriptional levels. BMC Immunol (2008) 1.07
Proximal genomic localization of STAT1 binding and regulated transcriptional activity. BMC Genomics (2006) 0.90
Visualizing infection spread: dual-color fluorescent reporting of virus-host interactions. Biotechnol Bioeng (2013) 0.84
Interferon Regulatory Factor 8 (IRF8) Impairs Induction of Interferon Induced with Tetratricopeptide Repeat Motif (IFIT) Gene Family Members. J Biol Chem (2016) 0.75
Nipah and Hendra Virus Nucleoproteins Inhibit Nuclear Accumulation of STAT1 and STAT2 by Interfering with Their Complex Formation. J Virol (2017) 0.75
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (1991) 2.54
Ribosomal precursor particles from yeast. Exp Cell Res (1975) 2.41
The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol (1992) 2.21
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res (1998) 2.10
Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem (1996) 2.05
Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem (1995) 2.02
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol (1997) 1.85
Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer (1991) 1.81
A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab Invest (1997) 1.74
Maturation of ribosomes in yeast. I Kinetic analysis by labelling of high molecular weight rRNA species. Biochim Biophys Acta (1976) 1.74
The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol (1991) 1.72
Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene (2011) 1.71
Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol (1999) 1.68
Nuclear import of the human androgen receptor. Biochem J (1993) 1.58
Evidence for a protective role of interferon in resistance to murine cytomegalovirus and its control by non-H-2-linked genes. Infect Immun (1982) 1.44
The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol (2006) 1.40
Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses. Proc Natl Acad Sci U S A (1995) 1.40
The N-terminal domain of the human androgen receptor is encoded by one, large exon. Mol Cell Endocrinol (1989) 1.38
Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res (1992) 1.34
Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol (1998) 1.26
Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry (1997) 1.24
Organization, structure and expression of murine interferon alpha genes. Nucleic Acids Res (1985) 1.24
Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem (1991) 1.20
Structure, chromosome localization, and regulation of expression of the interferon-regulated mouse Ifi54/Ifi56 gene family. Genomics (1994) 1.19
Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. Urol Res (1990) 1.14
A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol (1997) 1.12
Aberrant splicing of androgen receptor mRNA results in synthesis of a nonfunctional receptor protein in a patient with androgen insensitivity. Proc Natl Acad Sci U S A (1990) 1.10
Transcriptional regulation of androgen receptor gene expression in Sertoli cells and other cell types. Mol Cell Endocrinol (1992) 1.08
An exonic point mutation of the androgen receptor gene in a family with complete androgen insensitivity. Am J Hum Genet (1990) 1.06
Detailed analysis of the ribosomal RNA synthesis in yeast. Biochim Biophys Acta (1975) 1.06
Androgen receptor mutations. J Steroid Biochem Mol Biol (1995) 1.05
Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun (1989) 1.05
Characterization of the human androgen receptor transcription unit. J Biol Chem (1991) 1.03
Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. J Biol Chem (1993) 1.03
Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem J (1996) 1.01
Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta (1990) 1.01
Maturation of ribosomes in yeast. II. Position of the low molecular weight rRNA species in the maturation process. Biochim Biophys Acta (1976) 1.00
Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem (2000) 1.00
The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor. Clin Cancer Res (1997) 0.98
Characterization of the human kallikrein locus. Genomics (1992) 0.98
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Eur Urol (1995) 0.98
Hormone-dependent androgen receptor phosphorylation is accompanied by receptor transformation in human lymph node carcinoma of the prostate cells. J Biol Chem (1991) 0.98
Functional domains of the human androgen receptor. J Steroid Biochem Mol Biol (1992) 0.97
Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology (1997) 0.97
Changes in the abundance of androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites. Biochemistry (1994) 0.97
Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol (1991) 0.96
The human prostate-specific transglutaminase gene (TGM4): genomic organization, tissue-specific expression, and promoter characterization. Genomics (1998) 0.95
Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol (1990) 0.93
Structural organization of the human androgen receptor gene. J Mol Endocrinol (1989) 0.93
Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet (1993) 0.93
Transient expression of murine interferon-alpha genes in mouse and monkey cells. Gene (1986) 0.93
Interferon expression in the testes of transgenic mice leads to sterility. J Biol Chem (1988) 0.93
Molecular analysis of the androgen-receptor gene in a family with receptor-positive partial androgen insensitivity: an unusual type of intronic mutation. Am J Hum Genet (1997) 0.93
The mouse androgen receptor. Functional analysis of the protein and characterization of the gene. Biochem J (1991) 0.93
Chromosome region 8p11-p21: refined mapping and molecular alterations in breast cancer. Genes Chromosomes Cancer (1998) 0.92
E17K substitution in AKT1 in prostate cancer. Br J Cancer (2010) 0.91
Differential splicing of human androgen receptor pre-mRNA in X-linked Reifenstein syndrome, because of a deletion involving a putative branch site. Am J Hum Genet (1994) 0.91
The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett (1989) 0.90
PTEN-mediated G1 cell-cycle arrest in LNCaP prostate cancer cells is associated with altered expression of cell-cycle regulators. Prostate (2010) 0.90
Molecular cloning and characterization of novel prostate antigen cDNA's. Biochem Biophys Res Commun (1988) 0.88
The 56/58 kDa androgen-binding protein in male genital skin fibroblasts with a deleted androgen receptor gene. Mol Cell Endocrinol (1991) 0.88
Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol (1998) 0.87
Localization and hormonal stimulation of phosphorylation sites in the LNCaP-cell androgen receptor. Biochem J (1993) 0.87
Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun (1985) 0.87
Androgen receptor heterogeneity and phosphorylation in human LNCaP cells. Biochem Biophys Res Commun (1990) 0.86
Identification of mRNAs that show modulated expression during colon carcinoma cell differentiation. Eur J Biochem (1995) 0.86
Characterization of monoclonal antibodies raised against the prostatic cancer cell line PC-82. Prostate (1986) 0.86
Assignment of seven genes to distinct intervals on the midportion of human chromosome 19q surrounding the myotonic dystrophy gene region. Cytogenet Cell Genet (1990) 0.86
Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation. Int J Cancer (1999) 0.86
On the biosynthesis of 5.8 S ribosomal RNA in yeast. FEBS Lett (1975) 0.86
Threonine on amino acid position 868 in the human androgen receptor is essential for androgen binding specificity and functional activity. Biochem Biophys Res Commun (1993) 0.85
Synergism between androgens and protein kinase-C on androgen-regulated gene expression. Mol Cell Endocrinol (1995) 0.85
Properties of natural and hybrid murine alpha interferons. J Gen Virol (1986) 0.85
Structure-function analysis of murine interferon-alpha: antiviral properties of novel hybrid interferons. J Interferon Res (1988) 0.85
Prostate cancer schemes for androgen escape. Nat Med (2000) 0.85
Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer (1994) 0.84
A systematic study of interferon production by mouse L-929 cells induced with poly(I).poly(C) and DEAE-dextran. FEBS Lett (1979) 0.84
Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res (2000) 0.84
Characterization of polyclonal antibodies against the N-terminal domain of the human androgen receptor. Mol Cell Endocrinol (1989) 0.83
Androgen receptor abnormalities. J Steroid Biochem Mol Biol (1991) 0.83
Androgen receptor mutants that affect normal growth and development. Cancer Surv (1992) 0.83
Androgen regulation of the rat keratinocyte growth factor (KGF/FGF7) promoter. Biochem Biophys Res Commun (1996) 0.83
The human C/EBP delta (CRP3/CELF) gene: structure and chromosomal localization. Genomics (1993) 0.82
Mouse interferon alpha and beta genes are linked at the centromere proximal region of chromosome 4. J Gen Virol (1985) 0.82
Distinct antigenic character of two components of poly(I).poly(C)-induced mouse L cell interferon. FEBS Lett (1980) 0.82
Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Clin Cancer Res (1999) 0.82
The human prostatic carcinoma cell line LNCaP and its derivatives. An overview. Urol Res (1989) 0.82
Report of the Third International Workshop on Human Chromosome 8 Mapping. San Antonio, Texas, October 25-27, 1996. Cytogenet Cell Genet (1996) 0.81
A practical approach to the detection of androgen receptor gene mutations and pedigree analysis in families with x-linked androgen insensitivity. Pediatr Res (1994) 0.81